Icotinib HCl
Icotinib, also known as BPI-2009, is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation.
| Supplier | Alfa Cytology |
|---|---|
| Product # | BC0401 |
| Pricing | 5.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 100.0 mg, 200.0 mg, inquire |